Company profile
BridgeBio Pharma, Inc.
NASDAQ: BBIO · Healthcare · Biotechnology
#213 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
53DFH 37DQ 68GM 61SS 72
v0.1 · 65/100 weight · provisional
↑ market scale, filing timeliness · ↓ growth stability, balance-sheet leverage
Methodology →Revenue TTM
$580.0M
Rev growth YoY (TTM)
+355.2%
Net income (FY)
-$732.9M
Employees
839
as of 2026-08-05
Market cap
$16.1B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$502.1M$502.1M2025
Net income-$732.9M-$732.9M2025
Operating income-$523.4M-$523.4M2025
Total assets$936.0M$936.0M2025
Liabilities$3.0B$3.0B2025
Equity-$2.1B-$2.1B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product72%
License and Service26%
Royalty2%
By geography
Not disclosed.
The read
What is BridgeBio Pharma, Inc.’s revenue?
BridgeBio Pharma, Inc. booked $502.1M in FY2025 revenue, growing 126% year over year — faster than most Healthcare companies we track, at a -146.0% net margin.
Peers · Healthcare
Glaukos Corporation71BThe Oncology Institute, Inc.52DOncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst59CAscend Wellness Holdings, Inc.53DInyx, Inc.——Travere Therapeutics, Inc.74BNeighbors
Santa Clara →Key facts
CEONeil Kumar
SectorHealthcare
IndustryBiotechnology
HeadquartersPalo Alto, CA
ExchangeNASDAQ: BBIO
Employees839
IPO date2019-06-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.